Table 3.
Reported hypoglycemia in study participants
| Hypoglycemia | LM25 (N = 80) | IGL (N = 82) | ||
|---|---|---|---|---|
| Participants with ≥1 episode, n (%) |
Number of episodes per participant year, mean (SD) |
Participants with ≥1 episode, n (%) |
Number of episodes per participant year, mean (SD) |
|
| Overall (≤70 mg/dL) | 57 (71.3) | 18.9 (27.3) | 56 (68.3) | 21.6 (31.1) |
| Documented symptomatic (≤70 mg/dL) | 45 (56.3) | 9.6 (15.5) | 40 (48.8) | 11.0 (19.4) |
| Asymptomatic (≤70 mg/dL) | 36 (45.0) | 8.5 (17.9) | 43 (52.4) | 10.2 (20.9) |
| Nocturnal | 24 (30.0) | 2.4 (5.8) | 22 (26.8) | 2.8 (6.5) |
| Severe | 1 (1.3) | 0.1 (0.7) | 0 (0) | 0 (0) |
IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SD standard deviation